Biocytogen

Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

By NewsOnFloor 05 May 2023

Advertisment

Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based

By NewsOnFloor 05 May 2023

Share LinkedIn

Business

Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™. RenNano™ is the third member of the RenMic

By NewsOnFloor 03 May 2023

Share LinkedIn

Business

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant A

By NewsOnFloor 01 May 2023

Share LinkedIn

Business

Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an

By NewsOnFloor 24 Apr 2023

Share LinkedIn

Web Stories